BAD and thyroid cancer: LY294002 has already been used in preclinical studies [44], [45] and, consisting with the results shown here, its has been shown that its effect in reducing cell survival and tumor growth in mouse thyroid cancers is through a decrease in the phosphorylation of BAD and an increase in proapoptotic caspase 3 [45].